CClinicalTrials.gg
CompletedNCT05834933NBCRSUpdated Aug 3, 2023

Nigerian Breast Cancer Risk-Reduction Study

An interventional study of Individualized breast cancer risk assessment and Individualized breast cancer risk counselling in Risk Reduction Behavior, Breast Cancer and Health Behavior, sponsored by University of Ibadan. Completed at 4 sites in Nigeria. Open to female participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-03.

Sponsored by University of Ibadan · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 6 years after the study started (first participant enrolled Feb 2017, registered Mar 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
719
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
Female
01

Study summary

The study will be a randomized controlled trial. The aim of the study is to determine the Breast Cancer (BC) risk and to evaluate the effect of BC risk counseling on lifestyle changes and adherence to risk-reduction practices among first-degree female relatives of BC patients in South-West Nigeria. This study's research questions are:

  • What are the Nigeria Breast Cancer Study (NBCS) and Gail models estimates of the BC risk of first-degree female relatives of BC patients in South-West, Nigeria?
  • What are the effects of BC risk assessment and counseling on adherence to breast screening recommendations among first-degree female relatives of BC patients in South-West, Nigeria?
  • What are the effects of BC risk assessment and counseling on adherence to lifestyle risk reduction recommendations among first-degree female relatives of BC patients in South-West, Nigeria?
  • What is the knowledge, attitudes, and perception of first-degree female relatives of BC patients in South-West Nigeria towards genetic testing and BC etiology?
  • What factors predict breast screening among first-degree female relatives of BC patients in South-West Nigeria?
  • What factors predict the time to first BC screening (post-intervention) among first-degree female relatives of BC patients in South-West Nigeria?

Participants will be randomized into the control arm (standard care) and intervention arms of the study. The intervention arm of the study will have a BC risk assessment followed by individualized BC risk counseling. In addition, the intervention arm will receive BC awareness and MammaCare® BSE training. The control arm will receive only standard care comprising BC awareness and MammaCare® BSE training. Both study arms will receive BC screening recommendations and lifestyle modification recommendations.

We hope that the BC risk counseling will improve BC screening practices and modification of risk behaviors and this hypothesis will be tested.

02

Conditions studied

  • Risk Reduction Behavior
  • Breast Cancer
  • Health Behavior
  • Health Care Utilization
  • Health Knowledge, Attitudes, Practice

Browse trials for

Keywords

  • Breast cancer
  • First-degree relatives
  • Breast cancer prevention
  • Risk assessment
  • Risk counselling
  • Southwest Nigeria
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 719 is above the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Ibadan is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. First-degree female relatives of histologically diagnosed BC patients in the study sites
  2. Women aged 20 to 75 years of age
  3. Willingness to be contacted after six months for follow-up

Exclusion criteria

Exclusion Criteria:

  1. Personal history of BC
  2. Previous exposure to breast cancer risk assessment and counselling
  3. Absence of intact breasts
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
719 participants (actual)

Study arms

  • No intervention
    Standard care (SC)

    Participants received one-on-one breast cancer awareness education; one-on-one monthly Breast Self-Examination (BSE) training; general breast cancer screening recommendations; and general lifestyle modification recommendations

  • Experimental
    SC + Risk assessment and counselling

    Participants received Standard care as described in the SC arm above in addition to individualized breast cancer risk assessment, individualized breast cancer risk counseling, and lifestyle risk reduction recommendations

    Behavioral: Individualized breast cancer risk assessment · Behavioral: Individualized breast cancer risk counselling

Interventions

  • BehavioralIndividualized breast cancer risk assessment

    Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.

    Also known as: Risk assessment

  • BehavioralIndividualized breast cancer risk counselling

    Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The

    Also known as: Counseling

06

What researchers measure

Primary outcomes

  1. Effects of BC risk assessment and counselling on adherence to breast screening recommendations among first-degree female relatives of BC patients in South-West Nigeria

    Questionnaire will be administered to the participants to determine the effects of the intervention on adherence to breast screening practices

    Time frame: 6 months

  2. Effects of BC risk assessment and counselling on adherence to lifestyle risk reduction recommendations among first-degree female relatives of BC patients in South-West, Nigeria

    Questionnaire will be administered to the participants to determine the effects of the intervention on adherence to lifestyle risk reduction practices

    Time frame: 6 months

  3. Predictors of BSE among first-degree female relatives of BC patients in South-West Nigeria

    Statistical analysis will be carried out to determined the independent variables predicting BSE

    Time frame: 6 months

  4. Predictors of time to first BC screening post-intervention among first-degree female relatives of BC patients in South-West Nigeria

    Statistical analysis will be carried out to determined the independent variables predicting first time to BC screening

    Time frame: Baseline

Secondary outcomes

  1. Determine the perception of familial BC risk among first-degree female relatives of BC patients in South-West Nigeria.

    Semi-structured questionnaires will be used to determine the perception of familial BC risk among participants

    Time frame: Baseline

  2. Determine the knowledge of familiar BC risk among first-degree female relatives of BC patients in South-West Nigeria.

    Semi-structured questionnaires will be used to determine the knowledge of familiar BC risk among participants

    Time frame: Baseline

  3. Determine the knowledge, attitude, and perception towards genetic testing and BC aetiology among first-degree female relatives of BC patients in South-West Nigeria

    Semi-structured questionnaires will be used to determine the knowledge, attitude, and perception towards genetic testing and BC aetiology among participants

    Time frame: Baseline

07

Study locations

4 sites
  • Obafemi Awolowo University Teaching Hospital Complex (OAUTHC)
    Ile-Ife, Osun 5538, Nigeria
  • University College Hospital (UCH)
    Ibadan, Oyo 200285, Nigeria
  • Lagos State University Teaching Hospital (LASUTH)
    Lagos, 101233, Nigeria
  • Lagos University Teaching Hospital (LUTH)
    Lagos, 102215, Nigeria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05834933
Lead sponsor
University of Ibadan
Collaborators
Lagos State University Teaching Hospital (LASUTH), Obafemi Awolowo University Teaching Hospital, Lagos University Teaching Hospital (LUTH), University College Hospital, Ibadan
Responsible party
Agwai Celia Imaria (Epidemiologist, University of Ibadan) — Principal investigator
First posted
Apr 28, 2023
Start date
Feb 13, 2017
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021
Last update
Aug 3, 2023

Study contacts

OLADOSUN A OJENGBEDE, FMCOG, FWACS, FICS, M.B.B.S
principal investigator · CENTER FOR POPULATION AND REPRODUCTIVE HEALTH (CPRH), UNIVERSITY COLLEGE HOSPITAL, IBADAN
OLADELE O.O KALE, B.A, M.B, B.Ch, B.A.O
principal investigator · University of Ibadan
IKEOLUWAPO O. AJAYI, MBBS; PhD
principal investigator · University of Ibadan
CELIA IMARIA AGWAI, M.P.H; Ph.D.
principal investigator · University of Ibadan
DEZHENG HUO, PhD
study director · University of Chicago
OLUFUNMILAYO OLOPADE, M.D., F.A.C.P
study chair · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion